三维适形放射治疗联合肝动脉化疗栓塞及中药治疗原发性肝癌的临床研究

目的:探讨三维适形放射治疗(Three-dimensional Conformal Radiotherapy,3-DCRT)和肝动脉化疗栓塞(Transcatheter Arterial Chemoembolization,TACE)联合中药癌消软肝煎(Aixiao Ruanganjian,AXRGJ)治疗原发性肝癌的疗效及安全性。方法:124例原发性肝癌患者随机分为三维适形放射治疗和肝动脉化疗栓塞联合中药治疗组(综合组)41例、三维适形放射治疗和肝动脉化疗栓塞治疗组(放介组)44例和肝动脉化疗栓塞治疗组(介入组)39例,3个月治疗结束后,评价其临床疗效、生存率、免疫力及不良反应等。结果:综合组、放介组和介入组的总有效率分别为80.5%、77.3%和53.8%,综合组和放介组的总有效率与介入组的总有效率相比较,差异有显著性意义(P0.05)。3组患者的中位生存期分别为352天、341天和281天。综合组和放介组的中位生存期与介入组的中位生存期相比较,差异有显著性意义(P0.05)。6个月、12个月及24个月生存率综合组分别为80.5%、43.9%和14.6%;放介组分别为77.3%、40.9%和13.6%;介入组分别为53.8%、28.2%和7.7%;综合组和放介组的生存率与介入组的生存率相比较,差异有显著性意义(P0.05)。3组患者治疗前后免疫力(T淋巴细胞亚群)变化,综合组优于放介组与介入组,差异有显著性意义(P0.05)。综合组患者白细胞下降、血小板下降、血红蛋白下降和恶心呕吐等不良反应发生率均低于其他两组,差异有显著性意义(P0.05)。结论:三维适形放射治疗联合肝动脉化疗栓塞及中药癌消软肝煎治疗原发性肝癌有较好的疗效,毒副反应轻,患者耐受性好,安全可靠。

Clinical study on three-dimensional conformal radiotherapy and transcatheter arterial chemoembolization combined with Chinese medicine for primary herpatic carcinoma

Objective:To evaluate three-dimensional conformal radiotherapy(3-DCRT) and transcatheter arterial chemoembolization(TACE) combined with Aixiao Ruanganjian(AXRGJ) in treating primary herpatic carcinoma.Methods:One hundred and twenty four patients with primary herpatic carcinoma were randomly divided into 3-DCRT and TACE combining with AXRGJ group(n=41),3-DCRT combining with TACE group(n=44),and TACE alone group(n=39).The clinical effect,immunifunction and adverse reaction in the three groups were observed.Re...